Myeloid hemopathy

Myeloid hemopathy (also referred to as myeloid hematological neoplasm or myeloid hemopathy) is a broad grouping term used in Orphanet to classify a range of hematological disorders originating from the myeloid lineage of blood cells. Myeloid hemopathies encompass a heterogeneous group of conditions affecting the bone marrow and blood, in which abnormal proliferation, differentiation, or function of myeloid precursor cells leads to disease. This category includes conditions such as myelodysplastic syndromes, myeloproliferative neoplasms, acute myeloid leukemia, and related disorders. The myeloid lineage gives rise to red blood cells, platelets, and certain white blood cells (neutrophils, monocytes, eosinophils, basophils), so disruption in this lineage can affect multiple aspects of blood function. Clinical features vary widely depending on the specific subtype but commonly include anemia (fatigue, pallor, shortness of breath), thrombocytopenia (easy bruising, bleeding), leukopenia or leukocytosis (increased susceptibility to infections or elevated white blood cell counts), and splenomegaly. Some patients may present with bone pain, weight loss, night sweats, or other constitutional symptoms. The severity and prognosis depend heavily on the specific diagnosis within this broad category. Treatment approaches are highly variable and subtype-dependent, ranging from watchful waiting and supportive care (transfusions, growth factors) to intensive chemotherapy, targeted therapies (such as tyrosine kinase inhibitors for certain myeloproliferative neoplasms), hypomethylating agents for myelodysplastic syndromes, and allogeneic hematopoietic stem cell transplantation for eligible patients with aggressive disease. Advances in molecular characterization have led to increasingly personalized treatment strategies.

Common questions about Myeloid hemopathy